Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1456 to 1470 of 1976 results for nice guidelines

  1. NICE UK open content licence

    our content"}}]} NICE UK open content licence Reusing our content NICE syndication API NICE UK open content...

  2. Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessment (HTG766)

    Early value assessment (EVA) guidance on digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis.

  3. Cabotegravir for preventing HIV-1 in adults and young people (TA1106)

    Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.

  4. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  5. Naltrexone–bupropion for managing overweight and obesity (TA494)

    Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.

  6. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

  7. Laparoscopic mobilisation of the greater omentum for breast reconstruction (HTG162)

    Evidence-based recommendations on laparoscopic mobilisation of the greater omentum for breast reconstruction. This involves removing the fatty tissue using special instruments through small cuts in the abdomen.

  8. VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest (HTG765)

    Evidence-based recommendations on VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest. This involves using an artificial lung to oxygenate the blood outside the body.

  9. Terms and conditions

    "position":1,"item":{"@id":"/","name":"Home"}}]} Terms and conditions The NICE websites ("the websites") and all information contained...

  10. Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)

    Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.

  11. The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer (TA33)

    This guidance has been replaced by NICE technology appraisal guidance 93 [Replaced by NICE guideline CG131].

  12. Diabetes (type 2) - pioglitazone (TA21)

    This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].

  13. Taxanes for the treatment of breast cancer (TA6)

    This guidance has been replaced by NICE technology appraisal guidance 30 [Replaced by NICE guideline CG81].

  14. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

  15. Galaxy UNYCO for temporary stabilisation of lower limb fractures (MIB166)

    NICE has developed a medtech innovation briefing (MIB) on Galaxy UNYCO for temporary stabilisation of lower limb fractures .